Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 2/20 | 0.34 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21884614 | 0.83 | — | — | |
| SCHEMBL21884594 | 0.83 | LRRK2 (0.34) | GAASMN1; SMN2 | |
| SCHEMBL21884598 | 0.83 | CXCR1 (0.35) | GAASMN1; SMN2 | |
| SCHEMBL21884520 | 0.82 | AR (0.35) | HSD17B1HSD17B2CYP11B2CNR2GAA | |
| SCHEMBL21884575 | 0.81 | CNR2 (0.36) | HSD17B1HSD17B2CYP11B2CNR2 | |
| SCHEMBL23854877 | 0.81 | PPIA (0.39) | HSD17B1HSD17B2CNR2 | |
| SCHEMBL21884788 | 0.80 | PPIA (0.40) | CYP11B2CNR2 | |
| SCHEMBL21884491 | 0.80 | GAA (0.31) | GAASMN1; SMN2 | |
| SCHEMBL23854892 | 0.80 | LRRK2 (0.38) | GAASMN1; SMN2 | |
| SCHEMBL21884599 | 0.79 | HSD17B1 (0.35) | HSD17B1HSD17B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210371403-A1 | SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS | JNANA THERAPEUTICS INC. | 2021-12-02 | — | — | US | disclosed |
| US-20210371403-A1 | SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS | JNANA THERAPEUTICS INC. | 2021-12-02 | — | — | US | disclosed |
| US-20210299070-A1 | METHODS OF TREATING CREATINE TRANSPORTER DEFICIENCY | JNANA THERAPEUTICS INC. | 2021-09-30 | — | — | US | disclosed |
| US-20210299070-A1 | METHODS OF TREATING CREATINE TRANSPORTER DEFICIENCY | JNANA THERAPEUTICS INC. | 2021-09-30 | — | — | US | disclosed |
| WO-2020061473-A1 | SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS | JNANA THERAPEUTICS, INC. (US) | 2020-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210299070-A1 | METHODS OF TREATING CREATINE TRANSPORTER DEFICIENCY | SLC19A1, SLC1A5, SLC1A2 | HSD17B1 1039/4885HSD17B2 1221/4885CYP11B2 769/4885 |
| US-20210371403-A1 | SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS | SNRPE, G3BP1, G3BP2 | HSD17B1 4048/4885HSD17B2 4093/4885CYP11B2 4207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.